Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy

Détails

ID Serval
serval:BIB_1CE9365A5060
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy
Périodique
Transplantation
Auteur(s)
Toth  C. M., Pascual  M., Chung  R. T., Graeme-Cook  F., Dienstag  J. L., Bhan  A. K., Cosimi  A. B.
ISSN
0041-1337
Statut éditorial
Publié
Date de publication
11/1998
Peer-reviewed
Oui
Volume
66
Numéro
9
Pages
1254-8
Notes
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Nov 15
Résumé
Fibrosing cholestatic hepatitis (FCH) has recently been described after solid organ transplantation in patients with hepatitis C virus (HCV) infection. Typically, FCH is characterized by an ominous clinical course leading to progressive hepatic failure and death if liver transplantation is not performed. Two HCV-infected patients underwent cadaveric renal transplantation for end-stage renal disease resulting from membranous nephropathy and diabetic nephropathy. The time intervals between transplantation and the biopsy diagnosis of FCH for the two patients were 7 months and 10 years. Both patients presented with jaundice, hyperbilirubinemia, and mild-to-moderate elevations in serum aspartate aminotransferase. One patient was also found to have type II mixed cryoglobulinemia. Interferon-alpha therapy was begun after a diagnosis of FCH was established by liver biopsy. Liver test abnormalities normalized rapidly. When cholestatic hepatic deterioration develops in an HCV-infected organ allograft recipient, the diagnosis of FCH should be considered and a liver biopsy performed. Our observations indicate that FCH can respond to antiviral therapy.
Mots-clé
Aged Antiviral Agents/therapeutic use Cholestasis, Intrahepatic/drug therapy/*etiology/virology Hepacivirus/immunology Hepatitis C/*complications/drug therapy Hepatitis C Antibodies/blood Humans Interferon-alpha/therapeutic use Kidney Transplantation/*adverse effects Liver Cirrhosis/drug therapy/*etiology/virology Male Middle Aged
Pubmed
Web of science
Création de la notice
29/01/2008 14:52
Dernière modification de la notice
03/03/2018 14:33
Données d'usage